Scholars Central

Conference abstractPublished 27 Oct 2014

Biosimilar of protein therapeutics

Authors: Alok Bandyopadhyay

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Protein therapeutics, including monoclonal antibodies and cytokines, have become mainstream treatments in a number of clinical settings starting from pain control, cardiovascular to oncology. All these biological drugs are expensive.In order to develop inexpensive patients? treatments, biosimilar of these branded drugs are required. Formulation, manufacturing and various other chemistry, manufacturing and controls (CMC) information of the branded drugs are different from biosimilar. Manufacturing of the biological drugs are long multistep processes and complex. During formulation and manufacturing processes the drug product may be associated with product-related, process-related, and/or host-related impurities through degradation, deamidation, misfolding, or aggregation. When it is administered within the body, these impurities may also produce antibodies in addition to the antibody of drug substances. Moreover, protein aggregation in particular has long been associated with increased immunogenicity. Repeated administration of drug product may cause a break in immune tolerance that can adversely affect pharmacokinetics and clinical response. In addition, neutralizing antibodies that cross reacts with nonredundant proteins may be a cause of autoimmune reaction. Well designed formulation coupled with good protein purification scheme may sometimes reduce the formation of product related impurities and increase the stability of drug product. One of the best remedy will be to purify the drug product to homogeneity or near homogeneity retaining its stability and functional activity, which may not trigger immunogenicity or other clinical issues due to negligible content of impurities. At the same time more discussions with Agency are required for quicker review and approval like FDA?s ?breakthrough therapy pathway? for the drug used in life threatening more serious illness. Near homogeneous protein and frequent discussion with agency may open up the easier regulatory pathway for biosimilar approval. Interchangeability and price reduction issues may be solved at that time.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Alok Bandyopadhyay”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels